Eli Lilly and Co (MIC:LLY-RM) EBIT: ₽2,875,502.91 Mil (TTM As of Mar. 2026)


What is Eli Lilly and Co EBIT?

Eli Lilly and Co MIC:LLY-RM 98 EBIT is ₽2,875,502.91 Mil as of Mar. 2026. GuruFocus rates MIC:LLY-RM with a GF Score™ of 98/100. The stock has 6 warning signs investors should review.

Eli Lilly and Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₽794,843.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₽2,875,502.91 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eli Lilly and Co's annualized ROC % for the quarter that ended in Mar. 2026 was 38.60%. Eli Lilly and Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 101.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Eli Lilly and Co  (MIC:LLY-RM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eli Lilly and Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=3179375.432 * ( 1 - 16.43% )/( (6554223.266 + 7211797.648)/ 2 )
=2657004.0485224/6883010.457
=38.60 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8941414.679 - 1809413.026 - ( 577778.387 - max(0, 2800492.161 - 4422294.153+577778.387))
=6554223.266

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9476346.656 - 1835180.501 - ( 429368.507 - max(0, 2977941.286 - 4457482.405+429368.507))
=7211797.648

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Eli Lilly and Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3179375.432/( ( (1961489.258 + max(983606.492, 0)) + (2157410.104 + max(1151946.442, 0)) )/ 2 )
=3179375.432/( ( 2945095.75 + 3309356.546 )/ 2 )
=3179375.432/3127226.148
=101.67 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1411852.526 + 1092595.783 + 1149674.056) - (1809413.026 + 0 + 861102.847)
=983606.492

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1498075.011 + 1181047.905 + 1125608.805) - (1835180.501 + 0 + 817604.778)
=1151946.442

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eli Lilly and Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2875502.905/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co EBIT Related Terms

Eli Lilly and Co EBIT Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co EBIT Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 480,229.99 436,845.61 931,624.78 1,833,521.01 2,360,719.18

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 438,049.88 546,067.54 615,710.83 918,880.69 794,843.86

MIC:LLY-RM vs JNJ, ABBV, MRK: EBIT Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's EV-to-EBIT falls into.


Eli Lilly and Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₽2,875,502.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₽2,875,502.91 Mil mean?
Eli Lilly and Co (MIC:LLY-RM) has a EBIT of ₽2,875,502.91 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eli Lilly and Co.
Is Eli Lilly and Co's EBIT too high?
Eli Lilly and Co's current EBIT is ₽2,875,502.91 Mil. Overall, Eli Lilly and Co has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EBIT compare to JNJ and ABBV?
Eli Lilly and Co's EBIT of ₽2,875,502.91 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eli Lilly and Co. Eli Lilly and Co's current EBIT is ₽2,875,502.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Eli Lilly and Co (MIC:LLY-RM) has a current EBIT of ₽2,875,502.91 Mil. The current EBIT is ₽2,875,502.91 Mil. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eli Lilly and Co (MIC:LLY-RM), the current EBIT is ₽2,875,502.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.